On December 29, Zhejiang Wecome Pharmaceutical announced that due to suspected violations of information disclosure, the CSRC decided to file a case against the company and its actual controller Liu Zhongliang. The "case filing notice" was issued on December 27, 2024. In response, a reporter called Zhejiang Wecome Pharmaceutical as an investor, and relevant staff stated that the main issue involves Liu Zhongliang's fund occupation problem, which was previously under investigation and has now reached the case filing stage.
维康药业回应被立案：实控人存在资金占用问题
Zhejiang Wecome Pharmaceutical responds to being filed: the actual controller has a problem with fund occupation.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated